+1 410 659 2718
+1 410 659 2701
Senior Associate, Baltimore
Adriana Tibbitts is a senior associate in the Baltimore office of Hogan Lovells and is a member of the Corporate Practice Group and the Life Sciences Industry Sector Team, a multidisciplinary team focused on providing a full spectrum of services to clients involved in the Life Sciences industry.
Adriana advises publicly and privately held pharmaceutical, biotechnology, and medical device companies at all stages of development, as well as universities, in a broad range of transactional matters, including licensing and collaboration transactions, joint ventures, and other complex intellectual property-related transactions. Adriana also regularly counsels clients on mergers and acquisitions, product-specific acquisitions, divestitures and financing transactions, and the acquisition of pharmaceutical royalty streams. She also has experience structuring intercompany licensing and cost sharing arrangements.
Adriana has significant experience drafting and negotiating commercial contracts, including research agreements, services agreements, manufacturing and supply agreements, distribution agreements, clinical trial agreements, and technology transfer and material transfer agreements.
Adriana also advises clients, including venture capital funds and their portfolio companies, on general corporate matters and equity and debt financings.
Adriana was a summer associate at Hogan & Hartson (now Hogan Lovells) in 2007 and 2008. Adriana received a B.A. in Public Health from Johns Hopkins University and was awarded a Health Law Certificate for completing the Law and Healthcare Program at the University of Maryland Francis King Carey School of Law.
- Representation of Novartis in connection with its landmark portfolio transformation transactions valued at more than US$23 billion, including the acquisition by Novartis of GlaxoSmithKline's oncology business and the sale of Novartis's animal health business to Eli Lilly.
- Representation of the University of Pennsylvania in connection with its collaboration and license agreement with Novartis regarding novel CAR T-cell immunotherapies to treat cancer.
- Representation of Immune Design in connection with multiple licensing transactions, including (i) an exclusive license agreement with Sanofi for use of Immune Design's GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy, and (ii) a collaboration and license agreement with Sanofi to develop an immune therapy targeting the herpes simplex virus.
- Representation of Braeburn Pharmaceuticals in connection with transactional matters, including (i) the acquisition of a risperidone implant from Endo Pharmaceuticals, (ii) an exclusive license to a novel antipsychotic compound from Oncothyreon, and (iii) an exclusive license to Camurus's buprenorphine injection products.
- Representation of DRI Capital in multiple royalty monetization transactions, including the acquisition of a portion of the royalty stream for Benlysta.
- Representation of Vivus in its US$110 million synthetic royalty financing by Pharmakon Advisors to fund the commercialization of Qsymia.
- Representation of Intrexon in the establishment of exclusive channel collaboration agreements.
- Representation of TESARO, Rexahn Pharmaceuticals, Braeburn Pharmaceuticals, and other growth-stage pharmaceutical companies in connection with venture financings and general corporate and commercial matters.